NetworkNewsBreaks – CRISPR Therapeutics (NASDAQ: CRSP) Secures $315.2 Million in Underwritten Public Offering
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, has closed an underwritten public offering. According to the update, the offering consisted of 4,887,500 common stock shares, including 637,500 additional shares pursuant to the full exercise of the over-allotment option. CRISPR Therapeutics secured approximately $315.2 million in gross proceeds, with each of the shares sold at the public offering price of $64.50. ROTH Capital Partners acted as co-manager for the offering. To view the full press release, visit http://nnw.fm/S8Trq About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company focused on developing…







